Type 2 diabetes drug metformin recalled due to contamination with possible carcinogen

Two lots of a widely used type 2 diabetes medication, metformin, are being recalled due to possible contamination with a potentially cancer-causing compound. Metformin is designed to lower glucose levels.

Nostrum Laboratories Inc., based in Kansas City, 미주리, announced Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, 에 따르면 recall posted by the US Drug & Food Administration.
Testing revealed levels of nitrosamine, or NDMA, above acceptable limits in the recalled tablets.
The chemical NDMA is considered a possible carcinogen by the US Environmental Protection Agency. It’s an organic chemical used to make liquid rocket fuel and it can be a byproduct of manufacturing, including pharmaceutical manufacturing. It’s also found in water and foods, including meats, dairy and vegetables.
    NDMA has also been found in certain blood pressure drugs and antacid.
    This is the latest in a series of metformin recalls linked to potentially cancer-causing contaminants in the drugs.
    Nostrum said it has not received any reports of adverse events related to the recall. The company also said it was notifying its distributors and arranging for the return of the recalled product.
      The impacted product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301 which expiration date 05/2022. It can be identified as an off-white oblong tablet debossed withNM7.
      이상 34 million people in the US have diabetes — 약 1 에 10 — with approximately 90 ...에 95% of them being diagnosed with type 2 당뇨병, 에 따르면 미국 질병 통제 및 예방 센터.

      답장을 남겨주세요

      귀하의 이메일 주소는 공개되지 않습니다. 필요 입력 사항은 표시되어 있습니다 *